Phase II Trial of Niraparib ± Dostarlimab in Patients With Recurrent Endometrial Carcinoma

June 4-8, 2021; Online at https://conferences.asco.org/am
Niraparib plus dostarlimab yields a clinical benefit rate of 31.8% vs 20.0% with monotherapy in patients with recurrent EC enriched for platinum resistant disease.
Format: Microsoft PowerPoint (.ppt)
File Size: 453 KB
Released: June 8, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@clinicaloptions.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Gilead Sciences, Inc.
GlaxoSmithKline
Merck Sharp & Dohme Corp.

Related Content

Interactive algorithm tool with NCCN Guidelines® recommendations for Management of Immune Checkpoint Inhibitor–Related Toxicities v3.2021, from CCO

Released: July 22, 2021

On-demand webcast from a live Clinical Care Options (CCO) webinar on global perspectives on the use of PARP inhibitors for ovarian cancer, facilitated by Jonathan A. Ledermann, MD

Prof Jonathan A. Ledermann, MD, FRCP, FMed Sci person default Frederik Marmé, MD, PhD Prof Isabelle Ray Coquard Physicians: maximum of 0.75 AMA PRA Category 1 Credits Released: July 20, 2021 Expired: July 19, 2022

From Clinical Care Options (CCO), download a PDF featuring expert answers to clinician questions on CAR T-cell therapy

person default Caron A. Jacobson, MD Jae H. Park, MD Noopur Raje, MD Released: July 19, 2021

Downloadable PDF with highlights from a CCO podcast on managing endometrial and ovarian cancer with targeted therapies.

Robert L. Coleman, MD, FACOG, FACS Linda R. Duska, MD, MPH Leslie M. Randall, MD, MAS, FACS Released: July 16, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue